Masimo Corp is a global medical technology company that specializes in non-invasive monitoring solutions for patients. The company is best known for its innovative pulse oximetry technology, which measures blood oxygen levels and vital signs in real-time, providing healthcare professionals with critical data to enhance patient care. Masimo's products are designed to improve patient outcomes and safety across a wide range of clinical settings, including hospitals, outpatient facilities, and home care environments. In addition, the company develops advanced monitoring devices and software that integrate with existing medical systems, thereby optimizing workflows and enhancing the overall efficiency of healthcare delivery. Read More
Masimo (NASDAQ: MASI) today announced that its management will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 4:20 p.m. Pacific time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation.
Medical tech company Masimo (NASDAQ:MASI) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 24.5% year on year to $372 million. The company expects the full year’s revenue to be around $1.52 billion, close to analysts’ estimates. Its non-GAAP profit of $1.36 per share was 12.5% above analysts’ consensus estimates.
Masimo Corporation (Nasdaq: MASI), a leading global medical innovator, today announced that it has entered into a definitive agreement to sell its Sound United consumer audio business to HARMAN International (“HARMAN”), a wholly-owned subsidiary of Samsung Electronics Co., Ltd., for an aggregate purchase price of $350 million in cash, subject to certain adjustments. The sale follows the previously announced review of Masimo’s consumer audio business and will support the Company’s strategic focus on driving innovation in its core professional healthcare segment. The transaction is expected to close by the end of 2025, subject to receiving necessary regulatory approvals.
Masimo (NASDAQ: MASI) will release first quarter 2025 financial results for the period ended March 29, 2025, after the market closes on Tuesday, May 6, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 14.8%. This performance was worse than the S&P 500’s 8.5% decline.
Looking back on patient monitoring stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including iRhythm (NASDAQ:IRTC) and its peers.
Masimo (NASDAQ: MASI) today announced that its management will participate in the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 2:15 p.m. Eastern time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation.
What a fantastic six months it’s been for Masimo. Shares of the company have skyrocketed 45.8%, hitting $167.70. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on.
But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how ResMed (NYSE:RMD) and the rest of the patient monitoring stocks fared in Q4.
These large-cap stocks were top performers last week. Heico, Xpeng, Li Auto, Lineage, Erie Indemnity, Lloyds, Unum, FICO, Masimo, Smith & Nephew, AB InBev, and Nutanix all saw significant gains.
